Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
JAMA Ophthalmol. 2013 Apr;131(4):507-13. doi: 10.1001/jamaophthalmol.2013.2303.
This study adds to the evidence that elevated levels of high-sensitivity C-reactive protein (hsCRP) predict future risk of age-related macular degeneration (AMD). This information might shed light on underlying pathological mechanisms involving inflammation and could be of clinical utility in the identification of persons at high risk of AMD who may benefit from increased adherence to lifestyle recommendations, eye examination schedules, and therapeutic protocols.
To investigate the relationship between hsCRP and future risk of AMD in US men and women.
Pooled analysis of prospective nested case-control data from the Women's Health Study and 4 other cohorts, the Physicians' Health Study, Women's Antioxidant and Folic Acid Cardiovascular Study, Nurses' Health Study, and Health Professionals Follow-up Study.
A prospective nested case-control study within 5 large cohorts.
Patients were initially free of AMD. We prospectively identified 647 incident cases of AMD and selected age- and sex-matched controls for each AMD case (2 controls for each case with dry AMD or 3 controls for each case of neovascular AMD). MAIN OUTCOME MEASURES We measured hsCRP in baseline blood samples. We used conditional logistic regression models to examine the relationship between hsCRP and AMD and pooled findings using meta-analytic techniques.
After adjusting for cigarette smoking status, participants with high (>3 mg/L) compared with low (<1 mg/L) hsCRP levels had cohort-specific odds ratios (ORs) for incident AMD ranging from 0.94 (95% CI, 0.58-1.51) in the Physicians' Health Study to 2.59 (95% CI, 0.58-11.67) in the Women's Antioxidant and Folic Acid Cardiovascular Study. After testing for heterogeneity between studies (Q = 5.61; P = .23), we pooled findings across cohorts and observed a significantly increased risk of incident AMD for high vs low hsCRP levels (OR, 1.49; 95% CI, 1.06-2.08). Risk of neovascular AMD was also increased among those with high hsCRP levels (OR, 1.84; 95% CI, 1.14-2.98).
Overall, these pooled findings from 5 prospective cohorts add further evidence that elevated levels of hsCRP predict greater future risk of AMD. This information might shed light on underlying mechanisms and could be of clinical utility in the identification of persons at high risk of AMD who may benefit from increased adherence to lifestyle recommendations, eye examination schedules, and therapeutic protocols.
本研究进一步证明,高敏 C 反应蛋白(hsCRP)水平升高可预测年龄相关性黄斑变性(AMD)的未来发病风险。这一信息可能揭示了涉及炎症的潜在病理机制,并可能具有临床实用价值,有助于识别出 AMD 发病风险较高的人群,这些人群可能受益于增加对生活方式建议、眼部检查计划和治疗方案的依从性。
探讨 hsCRP 与美国男性和女性 AMD 未来发病风险的关系。
对妇女健康研究(Women's Health Study)和其他 4 个队列(内科医生健康研究、妇女抗氧化剂和叶酸心血管研究、护士健康研究和卫生专业人员随访研究)的前瞻性嵌套病例对照数据进行汇总分析。
5 个大型队列内的前瞻性嵌套病例对照研究。
患者最初均无 AMD。我们前瞻性地确定了 647 例 AMD 新发病例,并为每个 AMD 病例选择了年龄和性别匹配的对照(干型 AMD 病例每例选 2 个对照,新生血管型 AMD 病例每例选 3 个对照)。
我们在基线血样中检测 hsCRP。我们使用条件逻辑回归模型来检测 hsCRP 与 AMD 之间的关系,并使用荟萃分析技术汇总研究结果。
在校正吸烟状况后,与 hsCRP 水平较低(<1 mg/L)者相比,hsCRP 水平较高(>3 mg/L)者发生 AMD 的队列特异性比值比(OR)范围为内科医生健康研究中的 0.94(95%CI,0.58-1.51)到妇女抗氧化剂和叶酸心血管研究中的 2.59(95%CI,0.58-11.67)。在检验研究间异质性(Q=5.61;P=.23)后,我们对队列间结果进行汇总分析,发现 hsCRP 水平较高者发生 AMD 的风险显著增加(OR,1.49;95%CI,1.06-2.08)。hsCRP 水平较高者发生新生血管型 AMD 的风险也增加(OR,1.84;95%CI,1.14-2.98)。
总体而言,来自 5 个前瞻性队列的汇总结果进一步证明,hsCRP 水平升高可预测 AMD 的未来发病风险增加。这一信息可能揭示了潜在机制,并可能在识别 AMD 发病风险较高的人群方面具有临床实用价值,这些人群可能受益于增加对生活方式建议、眼部检查计划和治疗方案的依从性。